VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow VIVS
VivoSim Labs, Inc. (VIVS) Piotroski F-score
VivoSim Labs, Inc.'s Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | (1.00) |
| FY2025 | 4 | 2.00 |
| FY2024 | 2 | (3.00) |
| FY2020 | 5 | 1.00 |
| FY2019 | 4 | 0.00 |
| FY2018 | 4 | 0.00 |
| FY2017 | 4 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (125.64%) | (23.70%) | Fail | 0 |
| Positive operating cash flow | (10.83m) | (9.46m) | Fail | 0 |
| Rising return on assets | (125.64%) | (23.70%) | Fail | 0 |
| Cash flow above net income | 3.02m | (6.97m) | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 2.38 | 3.25 | Fail | 0 |
| No new shares issued | 2,588,000 | 1,464,000 | Fail | 0 |
| Rising gross margin | 100.00% | 96.53% | Pass | 1 |
| Rising asset turnover | 0.01 | 0.01 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| ONCO Onconetix, Inc. compare | 5 |
| DCOY Decoy Therapeutics Inc compare | 4 |
| ARAV ARAVIVE, INC compare | 3 |
| HCWB HCW Biologics Inc. compare | 3 |
| VIVS VivoSim Labs, Inc. | 3 |
| AFMDQ Affimed N.V. compare | 1 |
| SLXN Silexion Therapeutics Corp compare | — |
| BCAB BioAtla, Inc. compare | — |
| MBIO Mustang Bio, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover